Arrowhead Aims at Obesity’s Next Frontier With ARO‑INHBE

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has released new interim clinical data showing that its experimental obesity and liver disease drug ARO‑INHBE meaningfully cuts liver fat and improves key metabolic markers, both alone and when used with low‑dose tirzepatide.

What Arrowhead is testing with ARO‑INHBE

Arrowhead Pharmaceuticals is developing ARO‑INHBE as an RNA interference (RNAi) therapy that targets Activin E, a liver‑derived hormone linked to metabolic dysfunction, obesity, and metabolic dysfunction‑associated steatohepatitis (MASH).

The company shared Phase 1/2a interim results at the EASL 2026 liver congress, focusing on adults with obesity, with and without Type 2 diabetes.

In the study, ARO‑INHBE is given as an injection and is designed to “silence” the INHBE gene in the liver, lowering Activin E levels for months at a time with infrequent dosing.

This approach aims to tackle visceral fat and liver fat directly, addressing two drivers of MASH and obesity‑related metabolic disease.

Key clinical findings from the trial

The interim data show several important signals:

• Participants with obesity experienced dose‑dependent reductions in Activin E after a single dose of ARO‑INHBE, with the highest 400 mg dose cutting Activin E levels by a mean maximum of 85.3%, with effects lasting beyond three months.
• Among patients with obesity and baseline liver fat content above 8%, those receiving 200 mg or more of ARO‑INHBE monotherapy (n=10; baseline liver fat 14.5% ± 5.1%) saw a placebo‑adjusted reduction in liver fat content of 44%, which was statistically significant (p < 0.01).
• Longer exposure from Week 12 to Week 24 was linked to continued improvements in both visceral adipose tissue and liver fat, suggesting benefits deepen over time.
• When combined with low‑dose tirzepatide (5 mg), ARO‑INHBE produced greater reductions in visceral fat and liver fat than tirzepatide alone in patients with obesity, with or without Type 2 diabetes.

Safety has looked encouraging so far: ARO‑INHBE has been generally well tolerated as both monotherapy and in combination with tirzepatide, with most treatment‑emergent adverse events rated mild.

No participants stopped treatment because of side effects, and injection‑site reactions were typically mild and short‑lived.

Why this matters for Arrowhead investors

For Arrowhead Pharmaceuticals, ARO‑INHBE represents a potential new pillar in obesity and MASH, two of the largest and fastest‑growing markets in metabolic disease.

The data suggest ARO‑INHBE can significantly reduce liver fat and visceral fat with infrequent dosing and may work additively with established incretin drugs like tirzepatide